FDA Will Act on NRx Ketamine Application by November 10

The U.S. Food and Drug Administration set a November 10 goal date for reviewing an NRx Pharmaceuticals ketamine filing.

Updated on Sept. 20, 2026 in Substance Abuse

Isometric editorial illustration of a single glass medical vial on a clean surface, representing pharmaceutical regulatory processes. — The U.S. Food and Drug Administration has set a November 10 deadline to review an application from NRx Pharmaceuticals regarding its preservative-free ketamine product. AI Illustration. Upload story photo >

Live Poll

Will the FDA approve the NRx ketamine application on or before November 10, 2026?

The U.S. Food and Drug Administration has established a November 10 regulatory goal date for a pending ketamine application from NRx Pharmaceuticals. This update follows a decision by the agency to reclassify a recent filing amendment from major to minor.

Why it matters

The change in classification suggests the FDA anticipates the amendment regarding a preservative-free ketamine vial will require fewer agency resources than initially projected. This designation helps streamline the regulatory review process for this specific medical product.

The FDA issued the November 10 goal date under the Generic Drug User Fee Amendments. This adjustment occurs after the agency determined the filing amendment for preservative-free ketamine requires fewer regulatory resources.

The players

NRx Pharmaceuticals Inc.

This is a Wilmington, Delaware-based pharmaceutical company that focuses on developing treatments for central nervous system disorders.

U.S. Food and Drug Administration

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.

The details

NRx Pharmaceuticals Inc. received confirmation that its submission for preservative-free ketamine has been reclassified. The FDA determined the filing amendment does not require a substantial expenditure of agency resources, allowing for the expedited goal date.

November 10 is the established regulatory goal date for the FDA to take action on the application.

Health Landscape

The FDA is utilizing protocols established under the Generic Drug User Fee Amendments to manage the application review timeline. This action reflects broader regulatory efforts to streamline the approval process for medical products by reclassifying filings based on their complexity.

The regulatory timeline adjustment may eventually affect the availability of preservative-free ketamine options for healthcare providers. Patients and clinicians should monitor for further updates on the drug's approval status following the November 10 deadline.

The takeaway

The reclassification of the filing amendment signals a potential acceleration in the regulatory review process for this drug. Stakeholders should note that the November 10 date serves as a goal for agency action rather than a guaranteed date for final approval.